Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.59 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18607904 | 0.91 | CHRNA7 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18608149 | 0.91 | CHRNA7 (0.59) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15382227 | 0.88 | CHRNA7 (0.57) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL21164349 | 0.88 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL18612809 | 0.88 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL904139 | 0.86 | CHRNA7 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31196944 | 0.85 | CHRNA7 (0.65) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31000129 | 0.83 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29893635 | 0.83 | CHRNA7 (0.63) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1786140 | 0.82 | MEN1 (0.69) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CHRNA7 4487/4885HTR3E 4243/4885HTR3B 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.